Skip to main content
    J

    Janux Therapeutics Inc (JANX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.71
    -0.21 (-1.92%)

    Market Cap: $695.65M

    Last updated: Nov 17, 2026 at 4:18 PM ET

    Janux Therapeutics Inc (JANX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Janux Therapeutics (JANX) has a market cap of $695.65M and an enterprise value of $653.84M. Revenue grew 1994.69% over the last 12 months from the 12 months before. It kept -320.35% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 6.01% below the market cap, as cash exceeds debt.

    Market Cap$695.65M
    Enterprise Value$653.84M
    Latest price (Nov 17, 2026)$10.71

    Key Dates

    The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 24, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.24% in the quarter ended Sep 30, 2026 and grew 7.47% a year over 2 years.

    Shares Outstanding63.09M
    Shares Change (YoY)+1.72%
    Shares Change (QoQ)+0.24%
    Share Count Growth (2Y CAGR)+7.47%

    Valuation Ratios

    Sales and book value multiples are 29.0x and 0.7x. Its year-end P/S ranged from 47.9x to 157.9x from 2021 to 2025.

    P/S Ratio29.0x
    Forward P/S25.4x
    P/B Ratio0.7x

    Valuation history and multiples

    Price Statistics

    The stock is down 63.42% over 52 weeks and trades 34.81% below its 50-day average.

    Beta (1Y)0.92
    52-Week Change-63.42%
    1-Month Change-36.02%
    3-Month Change-38.87%
    6-Month Change-22.45%
    5-Year Change-28.25%
    Total Return (1Y)-63.42%
    Total Return (3Y CAGR)+7.25%
    Total Return (5Y CAGR)-10.85%
    Return vs SPY (1Y)-74.65%
    Max Drawdown (1Y)-69.17%
    Max Drawdown (3Y)-83.98%
    Sharpe Ratio (1Y)-1.05
    Correlation with SPY (1Y)0.13
    50-Day Average$16.43
    200-Day Average$15.33
    52-Week Range$10.73 to $35.34
    RSI (14 Days)27.1
    Average Volume (20 Days)1.03M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 17.69x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio17.69x
    Quick Ratio17.69x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -10.95% over the last 12 months, against a 5-year average of -12.83%.

    Return on Equity (ROE)-10.95%
    Return on Assets (ROA)-10.15%
    ROE (5Y Average)-12.83%
    ROA (5Y Average)-11.82%
    ROIC (5Y Average)-13.02%
    Asset Turnover0.03x
    Receivables Turnover83.17x

    Scores

    JANX has an Altman Z-Score of 5.69, in the safe zone above 2.99, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score5.69
    Altman Z ZoneSafe
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $31.17M over the last 12 months.

    Revenue$31.17M
    Revenue Growth (YoY)+1994.69%
    Gross Profit$22.23M
    Operating Income-$139.56M
    Pretax Income-$99.85M
    Net Income-$99.85M
    Reported EPS (TTM)-$1.59

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 92.68% of the $983.65M in total assets.

    Cash and Equivalents$41.82M
    Total Debt$0
    Net Cash$41.82M
    Net Cash Per Share$0.66
    Working Capital$905.13M
    Shareholder Equity$911.61M
    Book Value Per Share$14.45
    Total Assets$983.65M
    Total Liabilities$72.04M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $583.00K of capital spending, operating cash flow left -$54.16M of free cash flow.

    Operating Cash Flow-$53.58M
    Capital Expenditures$583.00K
    Free Cash Flow-$54.16M
    FCF Per Share-$0.89
    Depreciation and Amortization$14.22M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -447.76%.

    Gross Margin71.32%
    Operating Margin-447.76%
    Pretax Margin-320.35%
    Net Margin-320.35%
    FCF Margin-173.76%

    Growth

    Revenue grew 5.11% a year over 3 years.

    Revenue Growth (3Y CAGR)+5.11%
    Book Value Per Share Growth (2Y CAGR)+44.68%
    Tangible Book Per Share Growth (2Y CAGR)+44.68%

    Revenue and profit by year

    Dividends and Yields

    JANX does not pay a dividend. Its free cash flow yield is -8.02%.

    FCF Yield-8.02%
    Buyback Yield0.00%
    Shareholder Yield0.00%

    Peer Position

    Against 8 similar companies, JANX has the 3rd highest P/S.

    P/S Ratio29.0x vs 8.5x median
    Revenue Growth (Trailing 4 Quarters, YoY)+1994.69% vs -36.25% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -12.41% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-12.41%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About JANX

    What is JANX's market cap?

    Janux Therapeutics has a market cap of $695.65M. Its enterprise value, which adds debt and subtracts cash, is $653.84M.

    How many shares of JANX are outstanding?

    Janux Therapeutics has 63.09M shares outstanding. The count is up 1.72% from a year earlier.

    Does JANX pay a dividend?

    No. Janux Therapeutics does not pay a dividend.

    How much debt does JANX have?

    Janux Therapeutics has $0 of total debt and $41.82M of cash and equivalents, a net cash position of $41.82M.